Yahoo Finance

Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first ...

Ghent, Belgium – 15 November 2022 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload in liver disease, ...
PharmiWeb

Sequana Medical announces the successful completion of pre-clinical studies with its second-generation DSR product for congestive heart failure

Ghent, Belgium – 08 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of fluid overload in liver disease, heart failure and ...
Pharmabiz

Sequana Medical completes patient enrollment in phase 2a SAHARA I DSR study DSR 1.0 for congestive heart failure treatment

Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease and heart failure, announces the completion of enrollment in its phase 2a SAHARA proof-of-concept study ...
Yahoo Finance

Sequana Medical announces positive results from CHIHUAHUA, Phase 1 clinical trial of second-generation DSR product for congestive heart failure

Start of MOJAVE, a US multi-center randomized controlled Phase 1/2a clinical trial of DSR 2.0, planned for Q2 2023 Ghent, Belgium – 01 March 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the ...
PharmiWeb

Sequana Medical announces positive top-line results from SAHARA Ph. 2a study of DSR 1.0 in diuretic-resistant heart failure patients with persistent congestion and first ...

Safe, effective and rapid elimination of persistent congestion following intensive DSR therapy Considerable benefit in cardio-renal status maintained till end of study (16 weeks post-intensive DSR ...